FDA’s Potential Black Hole: House Investigates Departure Of Acting Head Of Medical Products Office
This article was originally published in The Gray Sheet
Energy and Commerce Committee letter states public information discrepancies raised questions about Leona Brenner-Gati’s status and “the circumstances surrounding her resignation.”
You may also be interested in...
The winning candidate would be the third to hold the position in two years. The job notice will be corrected, though – top secret clearance is not required.
Two deputy commissioners depart FDA. NICE takes over U.K. program to encourage adoption of new medical technologies. More news.
Richard Moscicki will fill new position that will help oversee center operations and provide “executive direction,” joining fellow deputy directors Robert Temple and Douglas Throckmorton.